In obesity-induced muscle atrophy, fibroblast growth factor 19 may promote mitochondrial biogenesis and antioxidant responses via the AMPK/PGC-1α pathway, thereby attenuating the effects of palmitate on mitochondrial dysfunction and oxidative stress [107]. The gene discussed is PPARGC1A; the disease is obesity due to melanocortin 4 receptor deficiency.